SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715725.
  • 2
    Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744748.
  • 3
    Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233240.
  • 4
    Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM, Smith K, de Waal Malefyt R, Kastelein RA, McClanahan TK, Bowman EP. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:25772587.
  • 5
    Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201206.
  • 6
    Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006;176:77687774.
  • 7
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:14611463.
  • 8
    Beyer BM, Ingram R, Ramanathan L, Reichert P, Le HV, Madison V, Orth P. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. J Mol Biol 2008;382:942955.
  • 9
    Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 2008;382:931941.
  • 10
    Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O′Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:56995708.
  • 11
    Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221242.
  • 12
    Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008;226:132146.
  • 13
    Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, Pendley CE, Cooper KD. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:49174926.
  • 14
    Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Engl J Med 2007;356:580592.
  • 15
    Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, Zhu Y, Pendley CE, Graham MA, Mascelli MA. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23:10811092.
  • 16
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:16651674.
  • 17
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:16751684.
  • 18
    Schmidt C. Ustekinumab poised to enter the psoriasis market. Nat Biotechnol 2008;26:13171318.
  • 19
    Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30:475477.
  • 20
    Binz HK, Pluckthun A. Engineered proteins as specific binding reagents. Curr Opin Biotechnol 2005;16:459469.
  • 21
    Nygren PA, Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004;290:328.
  • 22
    Gronwall C, Stahl S. Engineered affinity proteins—generation and applications. J Biotechnol 2009;140:254269.
  • 23
    Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 1995;8:601608.
  • 24
    Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772777.
  • 25
    Nygren PA, Uhlen M. Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997;7:463469.
  • 26
    Nord K, Nord O, Uhlen M, Kelley B, Ljungqvist C, Nygren PA. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem 2001;268:42694277.
  • 27
    Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev 2007;10:167175.
  • 28
    Gronwall C, Sjoberg A, Ramstrom M, Hoiden-Guthenberg I, Hober S, Jonasson P, Stahl S. Affibody-mediated transferrin depletion for proteomics applications. Biotechnol J 2007;2:13891398.
  • 29
    Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:26702680.
  • 30
    Johansson MU, Frick IM, Nilsson H, Kraulis PJ, Hober S, Jonasson P, Linhult M, Nygren PA, Uhlen M, Bjorck L, Drakenberg T, Forsen S, Wikstrom M. Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 2002;277:81148120.
  • 31
    Kraulis PJ, Jonasson P, Nygren PA, Uhlen M, Jendeberg L, Nilsson B, Kordel J. The serum albumin-binding domain of streptococcal protein G is a three-helical bundle: A heteronuclear NMR study. FEBS Lett 1996;378:190194.
  • 32
    Linhult M, Binz HK, Uhlen M, Hober S. Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci 2002;11:206213.
  • 33
    Lejon S, Frick IM, Bjorck L, Wikstrom M, Svensson S. Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 2004;279:4292442928.
  • 34
    Ahmad JN, Li J, Biedermannova L, Kuchar M, Sipova H, Semeradtova A, Cerny J, Petrokova H, Mikulecky P, Polinek J, Stanek O, Vondrasek J, Homola J, Maly J, Osicka R, Sebo P, Maly P. Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins: Struct Funct Bioinform 2012;80:774789.
  • 35
    Nilvebrant J, Alm T, Hober S, Lofblom J. Engineering bispecificity into a single albumin-binding domain. PLoS One 2011;6:e25791.
  • 36
    Nilvebrant J, Astrand M, Lofblom J, Hober S. Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. Cell Mol Life Sci 2013;70:39733985.
  • 37
    Vaisocherova H, Zitova A, Lachmanova M, Stepanek J, Kralikova S, Liboska R, Rejman D, Rosenberg I, Homola J. Investigating oligonucleotide hybridization at subnanomolar level by surface plasmon resonance biosensor method. Biopolymers 2006;82:394398.
  • 38
    Sipova H, Sevcu V, Kuchar M, Ahmad JN, Mikulecky P, Osicka R, Maly P, Homola J. Surface plasmon resonance biosensor based on engineered proteins for direct detection of interferon-gamma in diluted blood plasma. Sens Actuators B Chem 2012;174:306311.
  • 39
    Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942949.
  • 40
    Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008;181:59485955.
  • 41
    Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional Specialization of Interleukin-17 Family Members. Immunity 2011;34:149162.